Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Genetic alterations in endometrial cancer by targeted next-generation sequencing.

Chang YS, Huang HD, Yeh KT, Chang JG.

Exp Mol Pathol. 2016 Feb;100(1):8-12. doi: 10.1016/j.yexmp.2015.11.026. Epub 2015 Nov 25.

PMID:
26626801
2.

Identification of novel mutations in endometrial cancer patients by whole-exome sequencing.

Chang YS, Huang HD, Yeh KT, Chang JG.

Int J Oncol. 2017 May;50(5):1778-1784. doi: 10.3892/ijo.2017.3919. Epub 2017 Mar 20.

PMID:
28339086
3.

Tracking the origin of simultaneous endometrial and ovarian cancer by next-generation sequencing - a case report.

Valtcheva N, Lang FM, Noske A, Samartzis EP, Schmidt AM, Bellini E, Fink D, Moch H, Rechsteiner M, Dedes KJ, Wild PJ.

BMC Cancer. 2017 Jan 19;17(1):66. doi: 10.1186/s12885-017-3054-6.

4.

Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation.

Byron SA, Gartside MG, Wellens CL, Mallon MA, Keenan JB, Powell MA, Goodfellow PJ, Pollock PM.

Cancer Res. 2008 Sep 1;68(17):6902-7. doi: 10.1158/0008-5472.CAN-08-0770. Erratum in: Cancer Res. 2008 Dec 1;68(23):10005.

5.

Next-Generation Sequencing.

Le Gallo M, Lozy F, Bell DW.

Adv Exp Med Biol. 2017;943:119-148. Review.

PMID:
27910067
6.

Rapid Identification of FGFR2 Gene Mutations in Taiwanese Patients With Endometrial Cancer Using High-resolution Melting Analysis.

Lin YC, Er TK, Yeh KT, Hung CH, Chang JG.

Appl Immunohistochem Mol Morphol. 2015 Aug;23(7):532-7. doi: 10.1097/PAI.0000000000000114.

PMID:
25517871
7.

High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.

Garcia-Dios DA, Lambrechts D, Coenegrachts L, Vandenput I, Capoen A, Webb PM, Ferguson K; ANECS, Akslen LA, Claes B, Vergote I, Moerman P, Van Robays J, Marcickiewicz J, Salvesen HB, Spurdle AB, Amant F.

Gynecol Oncol. 2013 Feb;128(2):327-34. doi: 10.1016/j.ygyno.2012.11.037. Epub 2012 Dec 4.

PMID:
23219661
8.

FGFR2 alterations in endometrial carcinoma.

Gatius S, Velasco A, Azueta A, Santacana M, Pallares J, Valls J, Dolcet X, Prat J, Matias-Guiu X.

Mod Pathol. 2011 Nov;24(11):1500-10. doi: 10.1038/modpathol.2011.110. Epub 2011 Jul 1.

9.

Targeted mutation analysis of endometrial clear cell carcinoma.

Hoang LN, McConechy MK, Meng B, McIntyre JB, Ewanowich C, Gilks CB, Huntsman DG, Köbel M, Lee CH.

Histopathology. 2015 Apr;66(5):664-74. doi: 10.1111/his.12581. Epub 2015 Jan 13.

PMID:
25308272
10.

High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing.

Bourgon R, Lu S, Yan Y, Lackner MR, Wang W, Weigman V, Wang D, Guan Y, Ryner L, Koeppen H, Patel R, Hampton GM, Amler LC, Wang Y.

Clin Cancer Res. 2014 Apr 15;20(8):2080-91. doi: 10.1158/1078-0432.CCR-13-3114. Epub 2014 Feb 26.

11.

Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.

Myers AP, Filiaci VL, Zhang Y, Pearl M, Behbakht K, Makker V, Hanjani P, Zweizig S, Burke JJ 2nd, Downey G, Leslie KK, Van Hummelen P, Birrer MJ, Fleming GF.

Gynecol Oncol. 2016 Apr;141(1):43-8. doi: 10.1016/j.ygyno.2016.02.025.

12.

PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers.

Jin G, Kim MJ, Jeon HS, Choi JE, Kim DS, Lee EB, Cha SI, Yoon GS, Kim CH, Jung TH, Park JY.

Lung Cancer. 2010 Sep;69(3):279-83. doi: 10.1016/j.lungcan.2009.11.012. Epub 2009 Dec 16.

PMID:
20018398
13.

Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.

Beltran H, Yelensky R, Frampton GM, Park K, Downing SR, MacDonald TY, Jarosz M, Lipson D, Tagawa ST, Nanus DM, Stephens PJ, Mosquera JM, Cronin MT, Rubin MA.

Eur Urol. 2013 May;63(5):920-6. doi: 10.1016/j.eururo.2012.08.053. Epub 2012 Sep 5.

14.

Molecular genetic characterization of tamoxifen-associated endometrial cancer.

Prasad M, Wang H, Douglas W, Barakat RR, Ellenson LH.

Gynecol Oncol. 2005 Jan;96(1):25-31.

PMID:
15589576
15.

Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing.

Le Gallo M, Rudd ML, Urick ME, Hansen NF, Zhang S; NISC Comparative Sequencing Program, Lozy F, Sgroi DC, Vidal Bel A, Matias-Guiu X, Broaddus RR, Lu KH, Levine DA, Mutch DG, Goodfellow PJ, Salvesen HB, Mullikin JC, Bell DW.

Cancer. 2017 Sep 1;123(17):3261-3268. doi: 10.1002/cncr.30745. Epub 2017 May 9.

16.

Placing mitochondrial DNA mutations within the progression model of type I endometrial carcinoma.

Guerra F, Kurelac I, Cormio A, Zuntini R, Amato LB, Ceccarelli C, Santini D, Cormio G, Fracasso F, Selvaggi L, Resta L, Attimonelli M, Gadaleta MN, Gasparre G.

Hum Mol Genet. 2011 Jun 15;20(12):2394-405. doi: 10.1093/hmg/ddr146. Epub 2011 Apr 5.

PMID:
21470976
17.

Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer.

Bosse T, ter Haar NT, Seeber LM, v Diest PJ, Hes FJ, Vasen HF, Nout RA, Creutzberg CL, Morreau H, Smit VT.

Mod Pathol. 2013 Nov;26(11):1525-35. doi: 10.1038/modpathol.2013.96. Epub 2013 May 24.

18.

Disparate genomic characteristics of concurrent endometrial adenocarcinoma and ovarian granulosa cell tumor, revealed by targeted next-generation sequencing.

Choi YJ, Ho J, Lee A, Hur SY, Park HC, Park JS, Chung YJ, Lee SH.

Pathol Res Pract. 2018 Aug;214(8):1231-1233. doi: 10.1016/j.prp.2018.06.009. Epub 2018 Jun 19.

PMID:
29937308
19.

Molecular characterization of endometrial cancer: a correlative study assessing microsatellite instability, MLH1 hypermethylation, DNA mismatch repair protein expression, and PTEN, PIK3CA, KRAS, and BRAF mutation analysis.

Peterson LM, Kipp BR, Halling KC, Kerr SE, Smith DI, Distad TJ, Clayton AC, Medeiros F.

Int J Gynecol Pathol. 2012 May;31(3):195-205. doi: 10.1097/PGP.0b013e318231fc51.

PMID:
22498935
20.

High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated.

Krakstad C, Birkeland E, Seidel D, Kusonmano K, Petersen K, Mjøs S, Hoivik EA, Wik E, Halle MK, Øyan AM, Kalland KH, Werner HM, Trovik J, Salvesen H.

PLoS One. 2012;7(12):e52795. doi: 10.1371/journal.pone.0052795. Epub 2012 Dec 27.

Supplemental Content

Support Center